The Life Sciences team represented SVB Leerink LLC and Evercore Group LLC as underwriters on Centogene B.V.’s initial public offering of 4,000,000 of its common shares at a price of $14.00 per common share, for gross proceeds of $56.0 million. In addition, Centogene granted the underwriters a 30-day option to purchase up to an additional 600,000 common shares at the public offering price, less underwriting discounts and commissions.
Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. SVB Leerink LLC is a leading investment bank, specializing in healthcare and life sciences. Evercore Group LLC is a premier global independent investment banking advisory firm.
The Goodwin team was led by Michael Maline, Edwin O’Connor, Will Magioncalda, Jennifer Wong, and Kelvin Lin (Corporate); and included Stephanie Philbin and Elizabeth Mulkey (FDA/Regulatory); Roger Cohen, Allyson Maur, and Bryna Shmerling (Healthcare); Duncan Greenhalgh, Megan Gustafson, and Keith Chadwick (IP); and Stephan Kock, Dimitar Morfov, Kira Mueller, Friederike Hellmann, Christina Papadimitriou, and Carolin Keferstein (Goodwin Frankfurt); with invaluable assistance from Ettore Santucci (Opinions); Janet Andolina and Elle Srisirikul (Tax); and Nicholas Reist (Corporate).
For more information, read the press release.